GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Float Percentage Of Total Shares Outstanding

TYPTF (Tryptamine Therapeutics) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 06, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Tryptamine Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tryptamine Therapeutics's float shares is 0.00 Mil. Tryptamine Therapeutics's total shares outstanding is 1,438.92 Mil. Tryptamine Therapeutics's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tryptamine Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tryptamine Therapeutics's Institutional Ownership is 0.14%.

Tryptamine Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Tryptamine Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/1,438.92
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (OTCPK:TYPTF) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ASX:RAD ASX:PIQ ASX:CYP ASX:PTX ASX:NUZ ASX:SPL ASX:ILA ASX:LTP ASX:ATH ASX:EZZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
TYP:Australia
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Website
https://www.tryptherapeutics.com
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

From GuruFocus

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

By PRNewswire PRNewswire • 01-31-2022

Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines

By PRNewswire PRNewswire • 12-22-2021